WO1999051247A1 - Use of human mesenchymal stem cells to induce t-cell apoptosis - Google Patents
Use of human mesenchymal stem cells to induce t-cell apoptosis Download PDFInfo
- Publication number
- WO1999051247A1 WO1999051247A1 PCT/US1999/005349 US9905349W WO9951247A1 WO 1999051247 A1 WO1999051247 A1 WO 1999051247A1 US 9905349 W US9905349 W US 9905349W WO 9951247 A1 WO9951247 A1 WO 9951247A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- mesenchymal stem
- stem cells
- cell
- antigen
- Prior art date
Links
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims abstract description 65
- 230000033540 T cell apoptotic process Effects 0.000 title abstract description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 51
- 239000000427 antigen Substances 0.000 claims abstract description 35
- 102000036639 antigens Human genes 0.000 claims abstract description 33
- 108091007433 antigens Proteins 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 22
- 230000030833 cell death Effects 0.000 claims description 20
- 239000003446 ligand Substances 0.000 claims description 10
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims description 8
- 108010046080 CD27 Ligand Proteins 0.000 claims description 6
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 claims description 6
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 3
- 102100025221 CD70 antigen Human genes 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 abstract description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract description 3
- 230000008030 elimination Effects 0.000 abstract description 3
- 238000003379 elimination reaction Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 18
- 230000006907 apoptotic process Effects 0.000 description 15
- 208000023275 Autoimmune disease Diseases 0.000 description 13
- 230000028993 immune response Effects 0.000 description 12
- 210000000987 immune system Anatomy 0.000 description 12
- 238000011282 treatment Methods 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 101100044298 Drosophila melanogaster fand gene Proteins 0.000 description 5
- 101150064015 FAS gene Proteins 0.000 description 5
- 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 102000007499 CD27 Ligand Human genes 0.000 description 4
- 102100027207 CD27 antigen Human genes 0.000 description 4
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 4
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 description 4
- 108700012411 TNFSF10 Proteins 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 3
- 108010039471 Fas Ligand Protein Proteins 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 108010052621 fas Receptor Proteins 0.000 description 2
- 102000018823 fas Receptor Human genes 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 description 1
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 230000004518 activated T cell apoptosis Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000006450 immune cell response Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000004296 naive t lymphocyte Anatomy 0.000 description 1
- KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
- 229940124643 non-selective drug Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
- C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4637—Other peptides or polypeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46443—Growth factors
- A61K39/464433—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- the present invention relates to the field of inducing death of specific T- lymphocyte cells which are deleterious to an organism.
- the present invention relates particularly to the area of autoimmune disease in humans.
- T cell tolerance is achieved 1) in the thymus where thymocytes reactive for self-peptides are eliminated by clonal deletion (central tolerance), and 2) in the periphery by exposure to self-antigens under tolerogenic conditions (peripheral tolerance). Peripheral tolerance is manifested by clonal anergy, and by clonal deletion where autoreactive cells are elirninated.
- Clonal deletion can also result from expression of cell death molecules on the antigen presenting cells.
- Classic examples of death molecules are Fas ligand
- FasL FasL
- TRAIL ligand which ligate their receptors, Fas and DR4, respectively, on activated T cells, inducing apoptosis of the T cells.
- CD27 a member of the TNFR superfamily
- CD27-ligand CD70
- the immune system may generate a response against self- constituents, as happens in autoimmune disease.
- Autoimmune disease wherein antibodies or T cells attack self proteins, may be caused by abnormal immune response.
- the cause may be an autoreactive T cell component, the T cells may themselves be pathogenic, or T cells may help trigger autoreactive B cells to produce antibodies to self antigens.
- Patients with autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease and myasthenia gravis, are either inadequately treated with existing non-selective drug therapies, or experience deleterious side effects from long-term immunosuppressive treatment.
- human mesenchymal stem cells can be used to deliver antigens to the immune system for interaction with T cells.
- Mesenchymal stem cells can further be used to present to the immune system molecules that induce apoptotic death in cells of the immune system that express receptors for the molecules.
- the methods of the present invention are particularly useful for eliminating, reducing or ameliorating unwanted or activated T cell responses and can be used as a method to treat or inhibit specific unwanted or abnormal immune responses such as occurs in autoimmune disease.
- the method involves reducing, ameliorating or eliminating T cells that have been activated against an antigen by ad ⁇ unistering to a subject autologous human mesenchymal stem cells which have been modified to present such antigen, and to express a molecule that induces apoptosis of activated T cells.
- the mesenchymal stem cells can be used to deliver to the immune system a molecule that induces apoptosis of activated T cells since activated T cells carry a receptor for the molecule. This results in the deletion of activated T lymphocytes and in the suppression of an unwanted immune response.
- autologous human mesenchymal stem cells are modified to express a cell death molecule.
- the mesenchymal stem cells express the cell death molecule Fas ligand which will interact with the Fas receptor found on activated T cells.
- the method of the present invention provides administering to a host a human mesenchymal stem cell that (i) has been modified to have at least one exogenous antigen fragment bound to a primary surface molecule of the cell such that the antigen fragment is presented to the immune system, and (ii) has been modified to express a cell death molecule.
- the mesenchymal stem cell presents the antigen and thereby interacts with T cells that have previously been activated.
- the mesenchymal stem cells of the invention further contain exogenous genetic material that codes for a molecule that induces activated T cell apoptosis.
- the exogenous genetic materials are in one or more expression vectors.
- the mesenchymal stem cells are modified to deliver to the immune system a molecule that induces activated T cell elimination.
- the mesenchymal stem cells which may be allogeneic to the host, are modified to express a cell death molecule such as Fas ligand or TRAIL.
- a cell death molecule such as Fas ligand or TRAIL.
- the invention relates to methods for reducing, inhibiting or elin inating an immune response to an antigen, in vivo, by employing human mesenchymal stem cells to present antigen and to simultaneously present "a cell death molecule", a molecule that induces immune cell apoptosis.
- the administration of these modified mesenchymal stem cells results in the deletion of activated T cells and thus a reduction of the T cell response.
- the human mesenchymal stem cells are preferably autologous to the recipient of the human mesenchymal stem cells.
- the invention relates to a method of eliniinating activated T cells by administering, in vivo, mesenchymal stem cells which deliver a specific antigen to T cells, and in addition are modified to express a cell death molecule.
- the present invention is based in part on the discovery mat human mesenchymal stem cells do not provide costimulatory signals to fully stimulate T cells. Therefore, when antigen bearing mesenchymal stem cells are present in the immune system, the mesenchymal stem cells present the antigen without providing the costimulatory signal required for T cell activation.
- the mesenchymal stem cells are modified to present antigen to T cells by contacting the mesenchymal cells with antigen, in vitro, prior to contact with the T cells.
- the antigen can be a protein, a polypeptide, lipid or glycoprotein bound to a primary surface molecule of the cell.
- the mesenchymal stem cell is contacted with at least one antigen (antigen-pulsing) which the mesenchymal stem cell processes into an antigen fragment.
- the mesenchymal stem cells can alternatively be genetically manipulated to express an antigenic molecule.
- the mesenchymal stem cell contains exogenous genetic material that codes for at least one exogenous antigenic polypeptide, which the mesenchymal stem cell expresses, processes into an antigen fragment and presents to the T cells.
- the mesenchymal stem cells are modified to present an autoantigen, for example, an autoantigen that mediates the immune response in an autoirnmune disease.
- the mesenchymal stem cells are preferably autologous to the recipient of the mesenchymal stem cells. This method can be used to reduce or inhibit a T cell immune response involved in autoimmune disease, for example, rheumatoid arthritis, systemic lupus erythematosus, iriflammatory bowel disease and myastiienia gravis.
- autoimmune disease for example, rheumatoid arthritis, systemic lupus erythematosus, iriflammatory bowel disease and myastiariaa gravis.
- the mesenchymal stem cells are also modified to express a molecule that will induce T cell apoptosis, i.e., a cell death molecule.
- a cell death molecule is a molecule that interacts or binds with its cognate receptor on an activated T cell, the interaction inducing T cell death or apoptosis.
- the Fas system has been shown to be involved in a number of cell functions in vivo including negative selection of thymocytes, mamtaining immune privilege sites within the body, and cytotoxic T-lymphocyte (CTL)-mediated cytotoxicity (Green and Ware, PNAS 1997).
- CTL cytotoxic T-lymphocyte
- TRAIL receptor interacts with TRAIL ligand which can induce apoptosis in a variety of transformed cell lines (G. Pan SCIENCE, 1997); and the interaction of CD27 and its ligand CD70 (Prasad et al, PNAS 1997) also induces apoptosis.
- FasL expression is restricted to stimulated T cells and cites of immune privileges, TRAIL is detected in many normal tissues.
- Both TRAIL-ligand and CD70, but not Fas-ligand are expressed on unmanipulated human mesenchymal stem cells. Activated, but not resting, T cells express the TRAIL receptor and CD27.
- the mesenchymal stem cells can be induced to express an endogenous cell death molecule or can be genetically engineered to express exogenous molecules that cause cell death.
- the mesenchymal stem cells which present an antigen to which T cells have been previously activated cause the T cells to be drawn to such mesenchymal stem cells.
- the activated T cells express either TRALL-receptor, Fas or CD27 on the T cell.
- TRALL-receptor TRALL-receptor
- Fas Fas
- CD27 CD27 on the T cell.
- Other ligands either present within the mesenchymal stem cell or introduced into the mesenchymal stem cell can bind to their cognate receptors on the activated T cells to induce apoptosis.
- mesenchymal stem cells administered to an individual can delete autoreactive cells, reducing the severity or incidence of autoimmune disease.
- An advantage of the method of the present invention over current treatment for autoimmune disease is specificity; mesenchymal stem cells can be targeted to reduce a specific immune response while reducing or eliminating the effect on other segments of the immune system.
- the elimination of an antigen specific immune response enables the treatment of or prevention of an unwanted or abnormal hnmune response to a specific antigen.
- the methods of the present invention are particularly applicable to therapy of autoimmune disease and preferably el minate the response to autoantigen specifically, while reducing or el ⁇ riinating the effect on other aspects of the immune system.
- the invention can be utilized for treatment of autoimmune diseases where the autoantigen mediating the disease is known.
- the method involves genetically engineering mesenchymal stem cells, to express an autoantigen in order to induce specific immunotherapy to inactivate or elirninate abnormal immune responses.
- the invention encompasses administering the mesenchymal stem cells to a host as a method for the treatment of autoimmune diseases such as myasthenia gravis or rheumatoid arthritis.
- the mesenchymal stem cells are modified to express a molecule that will induce T cell apoptosis, without modification to present an antigen against which the T cells have been activated.
- the mesenchymal stem cells thus modified will have a nonspecific effect on the immune system, i.e., will eliminate activated T cells at or near the site of administration of the mesenchymal stem cells. Upon contact with the mesenchymal stem cells, apoptosis of the activated T cells will be induced.
- Mesenchymal stem cells are the formative pluripotential blast cells found, inter alia, in bone marrow, blood, dermis and periosteum. These cells can be expanded in culture, for example by methods described for isolating, purifying, and greatly replicating these cells in culture, i.e., in vitro, in Caplan and Haynesworth, U.S. Patent No. 5,486,359.
- the human mesenchymal stem cells of the invention can be engineered
- the engineered human mesenchymal stem cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying exogenous genes therein.
- the culture conditions such as temperature, pH and the like, can be those previously used with engineered human mesenchymal stem cells. See, for example, Gerson et al, U.S. Patent No. 5,591,625.
- the mesenchymal stem cells and method of the invention can be appropriately applied to treatment strategies requiring immunosuppressive reagents. Accordingly, the present invention provides for the modification of and expansion of mesenchymal stem cells in vitro for use in cellular immunotherapy, and the in vivo adrninistration of the immunosuppressive mesenchymal stem cells for treating or ameliorating unwanted immune responses.
- One aspect of the invention is the development of the mesenchymal stem cells into a vehicle for presenting antigen and delivering a cell death molecule for eliminating a specific cellular response.
- the dosage of the active ingredient varies within wide limits and will, of course be fitted to the individual requirements in each particular case.
- it is customary to adniinister from about 0.5 to about 5 million cells per kilogram of recipient body weight.
- the number of cells used will depend on the weight and condition of the recipient and other variables known to those of skill in the art.
- the cells can be adrninistered by a route which is suitable for the particular disease state to be treated.
- the antigen-modified mesenchymal stem cells can be targeted to a particular tissue or organ such as bone marrow.
- the cells can be suspended in an appropriate diluent, at a concentration of from about 5 x 10 6 to about 50 x 10 6 cells/ ml.
- Suitable excipients for injection solutions are those that are biologically and physiologically compatible with the recipient, such as buffered saline solution.
- the composition for administration should be sterile, stable and physiological acceptable. It is contemplated that the mesenchymal stem cells of the present invention can be used in conjunction with current modes of treating autoimmune disease. By ameliorating the severity of the immune response in autoirnmune disease, the amount of drug used in treatment and/or the frequency of adrninistration of drug therapy can be reduced, resulting in alleviation of general irnmune suppression and unwanted side effects.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU29041/99A AU2904199A (en) | 1998-04-03 | 1999-03-12 | Use of human mesenchymal stem cells to induce t-cell apoptosis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8053398P | 1998-04-03 | 1998-04-03 | |
US60/080,533 | 1998-04-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999051247A1 true WO1999051247A1 (en) | 1999-10-14 |
Family
ID=22157999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/005349 WO1999051247A1 (en) | 1998-04-03 | 1999-03-12 | Use of human mesenchymal stem cells to induce t-cell apoptosis |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2904199A (en) |
WO (1) | WO1999051247A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2824175A3 (en) * | 2004-03-22 | 2015-05-06 | Mesoblast International Sàrl | Mesenchymal stem cells and uses therefor |
US9528088B2 (en) | 2002-06-28 | 2016-12-27 | Life Technologies Corporation | Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994003202A1 (en) * | 1992-08-10 | 1994-02-17 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Interleukin-4 stimulated t lymphocyte cell death |
WO1995035321A1 (en) * | 1994-06-18 | 1995-12-28 | GSF - Forschungszentrum für Umwelt und Gesundheit GmbH | Antibodies against t-cells as therapeutics |
-
1999
- 1999-03-12 AU AU29041/99A patent/AU2904199A/en not_active Abandoned
- 1999-03-12 WO PCT/US1999/005349 patent/WO1999051247A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994003202A1 (en) * | 1992-08-10 | 1994-02-17 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Interleukin-4 stimulated t lymphocyte cell death |
WO1995035321A1 (en) * | 1994-06-18 | 1995-12-28 | GSF - Forschungszentrum für Umwelt und Gesundheit GmbH | Antibodies against t-cells as therapeutics |
Non-Patent Citations (1)
Title |
---|
BRUDER S P ET AL: "Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and followin cryopreservation.", JOURNAL OF CELLULAR BIOCHEMISTRY, (1997 FEB) 64 (2) 278-94. JOURNAL CODE: HNF. ISSN: 0730-2312., United States, XP002109558 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9528088B2 (en) | 2002-06-28 | 2016-12-27 | Life Technologies Corporation | Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation |
EP2824175A3 (en) * | 2004-03-22 | 2015-05-06 | Mesoblast International Sàrl | Mesenchymal stem cells and uses therefor |
US9694035B2 (en) | 2004-03-22 | 2017-07-04 | Mesoblast International Sarl | Mesenchymal stem cells and uses therefor |
EP2298862B1 (en) | 2004-03-22 | 2017-08-30 | Mesoblast International Sàrl | Mesenchymal stem cells and uses therefor |
US9943547B2 (en) | 2004-03-22 | 2018-04-17 | Mesoblast International Sàrl | Mesenchymal stem cells and uses therefor |
EP3461884A1 (en) * | 2004-03-22 | 2019-04-03 | Mesoblast International Sàrl | Mesenchymal stem cells and uses therefor |
US10668101B2 (en) | 2004-03-22 | 2020-06-02 | Mesoblast International Sárl | Mesenchymal stem cells and uses therefor |
US10716814B2 (en) | 2004-03-22 | 2020-07-21 | Mesoblast International Sàrl | Mesenchymal stem cells and uses therefor |
US10729727B2 (en) | 2004-03-22 | 2020-08-04 | Mesoblast International Sárl | Mesenchymal stem cells and uses therefor |
US10828334B1 (en) | 2004-03-22 | 2020-11-10 | Mesoblast International Sárl | Mesenchymal stem cells and uses therefor |
US10960025B2 (en) | 2004-03-22 | 2021-03-30 | Mesoblast International Sárl | Mesenchymal stem cells and uses therefor |
US11389484B2 (en) | 2004-03-22 | 2022-07-19 | Mesoblast International Sárl | Mesenchymal stem cells and uses therefor |
Also Published As
Publication number | Publication date |
---|---|
AU2904199A (en) | 1999-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6797269B2 (en) | Mesenchymal stem cells as immunosuppressants | |
KR100995340B1 (en) | Vaccine comprising Monocyte or immature myeloid cellsIMC which was loaded with the ligand of natural killer T cell and antigen | |
US20030147865A1 (en) | Cell therapy using immunoregulatory T-cells | |
US20060116321A1 (en) | Immunosuppressive exosomes | |
EP1997893A1 (en) | Compositions containing an OX-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response | |
US6410509B1 (en) | Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment | |
Lohoff et al. | The Th1/Th2 paradigm and experimental murine leishmaniasis | |
CA2253803A1 (en) | Use of interleukin-10 to produce a population of suppressor cells | |
WO2002072026A2 (en) | In situ langerhans cell vaccine | |
US20120195854A1 (en) | Granulysin in immunotherapy | |
EP1835933A2 (en) | Hsp60, hsp60 peptides and t cell vaccines for immunomodulation | |
Pleyer et al. | Gene therapy in immune-mediated diseases of the eye | |
WO1999051247A1 (en) | Use of human mesenchymal stem cells to induce t-cell apoptosis | |
KR101055666B1 (en) | Vaccine comprising Monocyte or immature myeloid cells(IMC) which was loaded with the ligand of natural killer T cell and antigen | |
EP3307298A1 (en) | Multi-peptide composition | |
US6884410B1 (en) | Methods for modulating antigen-specific immune responses | |
CA2338773A1 (en) | Ex vivo treatment of allogeneic and xenogeneic t-cells with gp39 antagonists | |
KR101290230B1 (en) | Dendritic cell based cancer medicine using M. tuberculosis Rv0652 protein as an adjuvant | |
Onji et al. | Dendritic cells and autoimmunity | |
WO1998051296A1 (en) | Method of reducing immunological tolerance to malignancy | |
Toker | Targeting Antigen Presenting Cells to Treat Autoimmune Inflammation | |
Won | Adoptive cell-based immunotherapy of cancer | |
Doubrovina et al. | Characterization of the tumor-specific activity of WT1 specific T cells generated in vitro from normal individuals by sensitization with WT1-peptide loaded autologous EBV transformed B cells | |
Verneris et al. | EX VIVO activated and expanded CD8+ T cells recognize malignant cells through a TCR independent and NKG2D dependent pathway | |
Jia | Modulation of dendritic cells with the interleukin-10 gene on polycation-modified polymeric particles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |